Danaher stock tumbled on Tuesday after the life sciences and diagnostics company's softer-than-expected core revenue outlook overshadowed solid second-quarter earnings.

Danaher stock fell 12% to $177.16 on Tuesday, making it the worst-performing S&P 500 component. The stock was set to log its largest daily percentage decline since September 17, 1991, according to Dow Jones Market Data.

Danaher before the opening bell on Tuesday posted adjusted earnings of $1.94 a share, from $1.80 a year ago and above Wall Street's expectation of $1.84. Revenue grew 5.5% to $6.26 billion, beating the analyst consensus call for $6.11 billion, according to FactSet.

Based on the second-quarter earnings results and an acquisition completed ahead of schedule, Danaher raised its full-year profit expectation to $8.45 to $8.60, from its previous $8.35 to $8.55 forecast. The analyst expectation is for Danaher to post full-year earnings of $8.45, according to FactSet.

However, the market reaction appears to be tied to Danaher's core revenue expectations. The company's third-quarter outlook calls for core revenue to increase 2% to 3% and Danaher narrowed its full-year forecast to 3% to 4% growth from the prior 3% to 6% expectation.

The Wall Street consensus expects third-quarter core revenue to grow 3.6%.

After digging deeper into the second-quarter financials, Citi Research analyst Patrick Donnelly called Danaher's results "mixed." The stock reaction says otherwise.

Suffice it to say that Danaher stock has suffered as of late. Shares are down about 10% this month and have declined 25% this year.

Write to Kit Norton at kit.norton@barrons.com

This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

July 21, 2026 10:29 ET (14:29 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.